Consensus Recommendations for the Management of Helicobacter pylori in Egypt: A 2026 Report

Helicobacter pylori infection is highly prevalent in Egypt and plays a central role in peptic ulcer disease, gastric cancer, and several extra-gastrointestinal disorders. Growing antibiotic resistance and emerging treatment options necessitate an updated national consensus to guide diagnosis and management strategies. We aimed to develop updated, evidence-based consensus recommendations for the management of H. pylori infection in Egypt, reflecting current international guidelines and regional clinical realities. A multidisciplinary expert panel reviewed studies on H. pylori published since 2018, including Egyptian data and updated global guidelines. Statements were developed across five domains: epidemiology, diagnosis, treatment, gastric cancer, and extra-gastroduodenal associations. Each statement was discussed and voted upon; consensus was defined as ≥70% agreement. This 2026 Egyptian consensus provides practical guidance on optimizing H. pylori diagnosis and eradication. Key updates include support for high-dose PPIs and vonoprazan-based therapy, expanded use of bismuth regimens, and validation of high-dose dual therapy as an effective option. Adoption of these recommendations aims to improve eradication success, reduce complications, and guide future public health strategies in Egypt.